Please login to the form below

Not currently logged in
Email:
Password:

Recordati acquires AstraZeneca blood pressure brands

Italian pharma firm obtains Seloken and Logimax

RecordatiRecordati has picked up the rights to two of AstraZeneca’s hypertension treatments as part of a $300m (€270m) deal.

The agreement sees the Milan-based pharmaceutical group acquire rights to AZ’s Seloken ZOK (metoprolol succinate) and Logimax fixed dose combination (metoprolol succinate and felodipine) treatments in Europe.

Metoprolol is a beta-blocker used mainly for conditions such as hypertension, angina pectoris and heart disorders.

Although both brands have been on the market for more than a decade, they still brought in around €100m last and Recordati is hoping they will help “reinforce its product portfolios in a number of its European subsidiaries, in particular Poland, France and Germany”.

The deal is expected to be completed in the coming weeks, after which AZ will be in-line for some additional royalties on the brands.

Andrea Recordati, vice chairman and CEO of Recordati, said: “We are very pleased with the agreement that we have entered into with AstraZeneca for the rights of their brands of metoprolol in Europe. Existing sales of the metoprolol brands will provide the base to enter new markets and thus complete our European geographical footprint.

“This new significant addition to our portfolio will strengthen our position in the European market and contribute to a further enhancement of our profitability margins.”

The with Recordati is the latest effort in AZ’s slimming drive, which has already seen it divest a number of non-core products to free up cash for its R&D plans.

Article by
Gemma Jones

25th May 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...